INFORMATION FOR
News
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its $60.2 million commitment to fund breast cancer research in 2023-2024, supporting more than 250 scientists at leading academic and medical institutions, including eight grants at Yale Cancer Center and Smilow Cancer Hospital.
A new study at Yale will concentrate on Black and Latina women and extend previous work on the links between breast cancer and lifestyle factors.
Dr. Sanft explains her role as a breast medical oncologist, as well as Director of the Survivorship Clinic and Patient Experience Officer.
In a new study, researchers at the Yale School of Public Health have confirmed a winning strategy or breast cancer survivors: healthy eating and exercise.
In the HOPE study reported in the Journal of Clinical Oncology, Irwin et al found that a program of aerobic exercise and strength training produced significant improvement in aromatase inhibitor–associated arthralgia in breast cancer survivors.
Yale cancer scientist Melinda Irwin says that the connection between obesity and cancer are so strong -- as are recent findings about the effectiveness of exercise and diet in treating cancer -- that pharmaceutical companies should be required to include these two lifestyle components in drug trials.
In an interview, Rachel Perry, PhD, discusses the link between insulin and cancer, a surprising finding in her research, and the future of precision medicine for metabolism-related cancers.
Smilow Shares with Primary Care: Breast Cancer
Eric Winer, MD, the director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital in New Haven, Connecticut, tells SELF that there’s not quite a consensus on when cis women and people assigned female at birth should begin getting mammograms.
Monica G. Valero, MD, assistant professor of surgery (oncology) and director of the Hispanic Breast Cancer Program, has received a prestigious one-year pilot grant from the American Cancer Society (ACS) to advance breast cancer care among the Hispanic population. The prestigious award affirms the Department of Surgery’s commitment to tackling health inequities on a national scale and locally.
No matter how metastatic breast cancer affects your love life, intimacy with your partner can still be meaningful and enjoyable.
Smilow Cancer Hospital, in partnership with the Norma Pfriem Breast Center, has opened a new patient care location in Bridgeport, CT to provide residents in the greater Bridgeport area with convenient access to Smilow Cancer Hospital specialty breast surgical care and expertise.
The Center for Breast Cancer at Smilow Cancer Hospital and Yale Cancer Center provides coordinated, state-of-the-art care for patients with benign and malignant diseases of the breast.
The Prudence Stiltor Crozier Breast Surgical Oncology Annual Lectureship and Resource Fund, to be guided by Mehra Goldhan, MD, MBA, aims to educate the next generation of breast surgeons.
Ellie Proussaloglou, MD, assistant professor of surgery (breast surgical oncology) discusses her fellowship at Yale and the transition from fellowship to being an attending.
Maryam Lustberg, director of the Center for Breast Cancer and chief of breast medical oncology at Yale Cancer Center and Smilow Cancer Hospital, says some promising advancements are already underway.
Researchers have revealed significant differences in the genetic characteristics of HER2-low advanced breast cancers, which may lead to the development of novel therapeutics for patients, according to recent findings presented at the 2023 San Antonio Breast Cancer Symposium.
New research illustrates remarkably lower use of immediate breast reconstruction in older women of Asian descent.
In a new study led by Yale Cancer Center researchers at Yale School of Medicine, their findings revealed important differences in the genetic makeup of HER2-low advanced breast cancers — a discovery that could lead to better treatment options for patients.
A team of researchers led by senior author Dr. David Rimm and first author Charles “Jack” Robbins at Yale Cancer Center evaluated a new “selective” biomarker called Troplex™, which assesses HER2, TROP2, and cytokeratin using quantitative immunofluorescence.